Effects of lactate on heart function in chronic heart failure patients
Physiological Effects of Lactate in Individuals With Chronic Heart Failure
This study tests how lactate affects heart function in people with chronic heart failure to see if it can help improve their symptoms.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Aarhus University Hospital Academic / other |
| Locations | 1 site (Aarhus, Region Midtjylland) |
| Trial ID | NCT06121323 on ClinicalTrials.gov |
What this trial studies
This study investigates how physiological levels of lactate influence the cardiovascular response in individuals suffering from chronic heart failure. By administering sodium lactate through infusion and ingestion, researchers aim to understand its effects on hemodynamics in this patient population. The study focuses on patients with a left ventricular ejection fraction of less than 40% and aims to provide insights into lactate's role as a signaling molecule and energy source during heart failure. The findings could help refine treatment approaches for managing heart failure symptoms.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with chronic heart failure, classified as NYHA II-III, with a left ventricular ejection fraction of less than 40%.
Not a fit: Patients with diabetes, significant cardiac valve disease, or severe comorbidities may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies that improve heart function and quality of life for patients with chronic heart failure.
How similar studies have performed: While the role of lactate in metabolism is well-studied, this specific investigation into its effects on chronic heart failure is novel and has not been extensively tested in previous studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chronic heart failure * NYHA II-III * Left ventricular ejection fraction \<40% * Negative urine-HCG for women with childbearing potential Exclusion Criteria: * Diabetes or HbA1c \>48 mmol/mol * Significant cardiac valve disease * Severe stable angina pectoris * Severe comorbidity as judged by the investigator * Inability to give informed consent * Age \<18 years * Other disease or treatment making subject unsuitable for study participation as judged by the investigator.
Where this trial is running
Aarhus, Region Midtjylland
- Aarhus University Hospital — Aarhus, Region Midtjylland, Denmark (Recruiting)
Study contacts
- Study coordinator: Niels A. Jespersen, MD
- Email: nije@clin.au.dk
- Phone: +45 22950990
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.